NRx Pharmaceuticals appoints Ira Strassberg as CFO and Treasurer effective March 15, 2022

NRX Pharmaceuticals, Inc.

Ira Strassberg appointed CFO and Treasurer effective March 15, 2022; had been financial consultant since August 2021.
Compensation: $400k base salary, $200k target bonus, and options for 425k shares at $3.10/share vesting over two years.
Previous roles include Deputy CFO of Cantor Fitzgerald, CFO of Cantor Commercial Real Estate, and senior roles at KPMG.
Severance: one-year base salary plus prorated bonus if terminated without cause or for good reason; accelerated vesting.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ira Strassberg

Chief Financial Officer and Treasurer

NRXP · NRX Pharmaceuticals, Inc.

Effective: 2022-03-15
Filed: March 18, 2022, 7:59 PM ET

On March 15, 2022, the Board of Directors of NRx Pharmaceuticals, Inc. (the “Company”) appointed Mr. Ira Strassberg, 55, to serve as Chief Financial Officer (CFO) and Treasurer of the Company effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Ira Strassberg was appointed as Chief Financial Officer and Treasurer at NRX Pharmaceuticals, Inc..

Action: appointed
Role: Chief Financial Officer and Treasurer

Exact text from the filing

On March 15, 2022, the Board of Directors of NRx Pharmaceuticals, Inc. (the “Company”) appointed Mr. Ira Strassberg, 55, to serve as Chief Financial Officer (CFO) and Treasurer of the Company effective immediately.

View on SEC.gov

NRX Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-22-003920

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.